NewEdge Advisors LLC Acquires 5,761 Shares of IDEXX Laboratories, Inc. $IDXX

NewEdge Advisors LLC increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 60.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,221 shares of the company’s stock after acquiring an additional 5,761 shares during the quarter. NewEdge Advisors LLC’s holdings in IDEXX Laboratories were worth $8,552,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in IDXX. SHP Wealth Management bought a new position in IDEXX Laboratories during the fourth quarter worth $26,000. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories in the third quarter valued at about $26,000. Mowery & Schoenfeld Wealth Management LLC lifted its stake in shares of IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after buying an additional 20 shares during the last quarter. Wormser Freres Gestion lifted its stake in shares of IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after buying an additional 47 shares during the last quarter. Finally, WealthCollab LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $30,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX stock opened at $586.67 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. The company’s 50-day simple moving average is $559.73 and its 200 day simple moving average is $584.88. IDEXX Laboratories, Inc. has a 52 week low of $518.55 and a 52 week high of $769.98. The company has a market capitalization of $46.22 billion, a PE ratio of 41.26, a price-to-earnings-growth ratio of 3.18 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.IDEXX Laboratories’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.82 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on IDXX. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup boosted their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday. UBS Group upped their target price on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $756.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.